Our observation that the negative modulation of REV-ERBα (either by pharmacological or specific genetic inhibition) provides partial protection for glucotoxicity- and cytokines-induced β-cell apoptosis point to REV-ERBα as a potential new therapeutic target to modulate autophagy, protein degradation and β-cell survival in diabetes. Here, NR1D1 is linked to diabetes mellitus.